CoChat

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

Open access
Menon, Malini, Elliott, Richard, Bowers, Leandra, Balan, Nicolae, Rafiq, Rumana, Costa-Cabral, Sara, Munkonge, Felix, Trinidade, Ines, Porter, Roderick, Campbell, Andrew D., Johnson, Emma R., Esdar, Christina, Buchstaller, Hans-Peter, Leuthner, Birgitta, Rohdich, Felix, Schneider, Richard, Sansom, Owen, Wienke, Dirk, Ashworth, Alan, Lord, Christopher J. · 2019 · Scientific Reports
Cited by 60

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Inhibition of the PARP superfamily tankyrase enzymes suppresses Wnt/β-catenin signalling in tumour cells. Here, we describe here a novel, drug-like small molecule inhibitor of tankyrase MSC2504877 that inhibits the growth of APC mutant colorectal tumour cells. Parallel siRNA and drug sensitivity screens showed that the clinical CDK4/6 inhibitor palbociclib, causes enhanced sensitivity to MSC2504877. This tankyrase inhibitor-CDK4/6 inhibitor combinatorial effect is not limited to palbociclib and MSC2504877 and is elicited with other CDK4/6 inhibitors and toolbox tankyrase inhibitors. The addition of MSC2504877 to palbociclib enhances G 1 cell cycle arrest and cellular senescence in tumour cells. MSC2504877 exposure suppresses the upregulation of Cyclin D2 and Cyclin E2 caused by palbociclib and enhances the suppression of phospho-Rb, providing a mechanistic explanation for these effects. The combination of MSC2504877 and palbociclib was also effective in suppressing the cellular hyperproliferative phenotype seen in Apc defective intestinal stem cells in vivo. However, the presence of an oncogenic Kras p.G12D mutation in mice reversed the effects of the MSC2504877/palbociclib combination, suggesting one molecular route that could lead to drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-018-36447-4

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 60

Metadata

Authors
Menon, M., Elliott, R., Bowers, L., Balan, N., Rafiq, R., Costa-Cabral, S., Munkonge, F., Trinidade, I., Porter, R., Campbell, A. D., Johnson, E. R., Esdar, C., Buchstaller, H.-P., Leuthner, B., Rohdich, F., Schneider, R., Sansom, O., Wienke, D., Ashworth, A., & Lord, C. J.
Venue
Scientific Reports
Published
2019-01-17
Volume
9
Issue
1
Pages
201-201
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2909403286
Cited by
60
References
5
FWCI
2.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. https://app.cochat.ai/papers/10.1038/s41598-018-36447-4
The paper
Menon, M., Elliott, R., Bowers, L., Balan, N., Rafiq, R., Costa-Cabral, S., Munkonge, F., Trinidade, I., Porter, R., Campbell, A. D., Johnson, E. R., Esdar, C., Buchstaller, H.-P., Leuthner, B., Rohdich, F., Schneider, R., Sansom, O., Wienke, D., Ashworth, A., & Lord, C. J. (2019). A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. Scientific Reports. https://doi.org/10.1038/s41598-018-36447-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.